• Latest Posts

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What do the CAR-T Patient Deaths Mean for the Future of the Field?

Would you Taste this Gene-Edited Dinner?

Debunking the Immuno-Oncology Hype: is it as good as it sounds?

UPDATED: Storm on the CAR-T field – 3 patients die in Phase II Study

Cellectis gets paid for a first Milestone, Investors are pleased


How Good was 2015 for the French Universal CAR-T Biotech?

7 Trendy European Biotechs Listed on the NASDAQ in 2016

Cancer: World Best Ever CAR-T Results have Just been Disclosed

The European Union Finances the Future of CAR-T Manufacturing